3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Brain Neoplasms
3
Xanthomatosis, Cerebrotendinous
1
Recurrence
1
Oligodendroglioma
1
Melanoma
1
Medulloblastoma
1
Influenza, Human
1
Glioma
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
25
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
Diphtheria-Tetanus Vaccine
×
Clear all
NCT02193347
2023-12-01
RESIST
Duke University
Phase 1
Completed
24 enrolled
8 charts